Clinical insights

Key research benefits

An FDA-approved (2010, Egrifta), stabilized GHRH analog — the growth-hormone peptide with the strongest human clinical trial base.

  • ~15% visceral fat reduction in a 412-patient, 26-week randomized trial; a 2026 meta-analysis of 5 RCTs confirmed the effect plus a 1.42 kg lean mass increase.
  • ~37% reduction in liver fat, with fibrosis progression cut from 37% to 10% in a dedicated fatty-liver trial.
  • FDA-approved therapeutic with the deepest published safety record of any GH-secretagogue in this guide.

Research backing

Falutz et al., NEJM 2007 & JAIDS 2010 (pivotal 412-patient trial); Stanley et al., Lancet HIV 2019 (NAFLD trial); Badran et al., 2026 meta-analysis (5 RCTs). All major trials were in HIV-associated lipodystrophy populations.

Research Grade Formula

Tesamorelin

Muscle Growth & Hormone Optimization

Tesamorelin · 10mg

4.9 (312 reviews)

$145

Express Shipping $20 — Australia only

  • Third-party tested
  • Non-GMO
  • GMP certified
How to use

Follow research handling and reconstitution guidance for this compound. Always use appropriate lab technique and sterile materials.

Research Dosage Protocol
What's inside

The vial contains Tesamorelin, a GHRH-analogue research peptide used in endocrine and body-composition laboratory models. Packaged as a lyophilized powder for controlled reconstitution.

Technical overview

  • Contents: Tesamorelin research peptide, 10 mg class vial
  • Class: Growth hormone–releasing hormone analogue
  • Purity: ≥99% with batch Certificate of Analysis
  • Appearance: White lyophilized powder
  • Reconstitution: Bacteriostatic water; maintain sterile technique
  • Post-mix storage: Refrigerate and use within standard research windows

Reconstitute with bacteriostatic water at room temperature. For laboratory research and educational use only — not for human consumption.

Customer reviews

4.9

Based on 312 reviews